BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp., a clinical-stage biotech company focused on cancer immunotherapies, announced a $5 million at-the-market offering under Nasdaq rules. The offering includes over 5 million common shares and warrants, with the funds intended for working capital, corporate purposes, and advancing business objectives. The offering is expected to close on October 2, 2024, with ThinkEquity serving as the sole placement agent.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
